Table 1 Comparison of clinicopathologic variables and PIK3CA mutation status in 280 primary endometrial carcinomas assessed by Sanger sequencing.
PIK3CA mutation | Total cases n | No | Yes | p-valuea |
|---|---|---|---|---|
Variable | n (%) | n (%) | ||
Age | 280 | 0.4 | ||
<66 | 123 (86.6) | 19 (13.4) | ||
≥66 | 114 (82.6) | 24 (17.4) | ||
BMI | 271 | 0.6 | ||
<30 | 153 (83.6) | 30 (16.4) | ||
≥30 | 76 (86.4) | 12 (13.6) | ||
FIGO stage | 280 | 0.8 | ||
I-II | 191 (84.9) | 34 (15.1) | ||
III-IV | 46 (83.6) | 9 (16.4) | ||
Myometrial infiltration | 278 | 0.1 | ||
<50% infiltration | 140 (88.1) | 19 (11.9) | ||
≥50% infiltration | 96 (80.7) | 23 (19.3) | ||
Lymph node metastasis | 235 | 0.9 | ||
No | 170 (84.2) | 32 (15.8) | ||
Yes | 28 (84.8) | 5 (15.8) | ||
Histologic type | 280 | 0.4 | ||
Endometrioid | 195 (85.5) | 33 (14.5) | ||
Non-Endometrioid | 42 (80.8) | 10 (19.2) | ||
Grade | 277 | 0.6 | ||
High-medium | 149 (85.6) | 25 (14.4) | ||
Low | 85 (83.3) | 17 (16.7) | ||
DNA ploidy | 231 | 0.4 | ||
Diploid | 147 (86.0) | 24 (14.0) | ||
Aneuploid | 49 (81.7) | 11 (18.3) | ||
ERα | 273 | 0.8 | ||
Positive | 175 (85.3) | 31 (15.0) | ||
Negative | 56 (83.6) | 11 (16.4) | ||
PR | 276 | 0.6 | ||
Positive | 174 (84.1) | 33 (15.9) | ||
Negative | 60 (87.0) | 9 (13.0) |
